((自动化翻译由路透提供，请见免责声明 ))
12月31日 - ** 药品分销商在 2024 年年末业绩大增，原因是他们扩大了在治疗类风湿性关节炎和癌症等复杂疾病的特药市场的影响力，这得益于他们的高利润率
** Cardinal 、Cencora 和McKesson 今年分别增长17.4%、9.2%和23%。
** 这些公司在 2024 年进行了大量收购，因为它们选择加倍努力发展业务
** 8 月，MCK 以 24.9 亿美元收购了 (link) 社区癌症中心佛罗里达癌症专科与研究所的业务和行政服务部门的控股权。
** CAH 玩起了 "追赶 "游戏，在今年的四项交易中斥资 60 多亿美元，而 COR 则在 11 月达成了一项 46 亿美元的交易 (link)，为其医生管理服务组合增加了近 300 名眼科专家。
** 标准普尔 500 保健分销商子指数 今年增长了 13.9
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.